Description
Title: Is there a benefit to PAH-specific therapy for diffuse parenchymal lung diseases with pulmonary hypertension?
Abstract: In 40–50% of patients with diffuse parenchymal lung disease (DPLD) at the end stage, pulmonary hypertension (PH) is identified, and it is linked to a significant reduction in life expectancy. The best DPLD treatment currently available and long-term oxygen therapy are advised for patients with PaO2 less than 60 mm Hg, according to the most recent ERS/ESC guidelines. Drugs that target pulmonary arterial hypertension (PAH) are not advised for use in patients with PH-DPLD because they run the risk of worsening hypoxemia by widening the ventilation-perfusion mismatch. However, some patient populations may benefit from PAH-focused treatment. What should the candidate for PAH-specific therapy look like? What drug class is most promising? What outcome measures should be used? These are just a few of the significant questions the authors attempt to address.
Keywords: pulmonary hypertension, diffuse parenchymal lung diseases, PAH-specific therapy
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Advances in Respiratory Medicine
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.